News
LLY
744.62
-0.18%
-1.33
Exploring The Competitive Space: Eli Lilly and Co Versus Industry Peers In Pharmaceuticals
Eli Lilly and Co is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. The company is a major player in the Pharmaceuticals industry. Eli Lilly is trading at a higher price to earnings ratio than its peers in the industry.
Benzinga · 7h ago
Validea Detailed Fundamental Analysis - LLY
NASDAQ · 10h ago
Noteworthy Thursday Option Activity: RILY, LLY, GLNG
NASDAQ · 1d ago
Patients Find Weight Loss Drug Zepbound A Game Changer, But Makers See Production Delay Until 2025
The GLP-1 class of drugs for weight loss has gained tremendous popularity but is struggling with a shortage that could extend into 2025. The weight loss drug frenzy took off when the FDA approved Novo Nordisk’s Wegvoy in 2021. Limited supplies of diabetes drug Mounjaro and weight-loss drug Zepbound are expected through the second quarter of this year.
Benzinga · 1d ago
India's Biocon developing its own version of Wegovy, clinical trial likely next year
India's Biocon developing its own version of Novo Nordisk's Wegovy, clinical trial likely year. Wall Street has forecast the market for obesity treatments reaching at least $100 billion by the end of the decade. Biocon is looking to grab a piece of the exploding weight-loss drug market.
Reuters · 1d ago
XLV, LLY, UNH, TMO: Large Outflows Detected at ETF
NASDAQ · 1d ago
Here's How Much You Would Have Made Owning Eli Lilly and Co Stock In The Last 15 Years
Eli Lilly and Co has outperformed the market over the past 15 years by 10.71% on an annualized basis. If an investor had bought $1000 of LLY stock 15 years ago, it would be worth $22,769.62 today. LLY has an average annual return of 23.13%.
Benzinga · 1d ago
Eli Lilly Price Target Maintained With a $815.00/Share by Cantor Fitzgerald
Dow Jones · 1d ago
Cantor Fitzgerald Reiterates Overweight on Eli Lilly and Co, Maintains $815 Price Target
Benzinga · 1d ago
Analysts Are Bullish on These Healthcare Stocks: Eli Lilly & Co (LLY), TG Therapeutics (TGTX)
TipRanks · 1d ago
Analysts Conflicted on These Healthcare Names: Intra-Cellular Therapies (ITCI), Eli Lilly & Co (LLY) and Sanofi (OtherSNYNF)
TipRanks · 1d ago
Guru Fundamental Report for LLY
NASDAQ · 1d ago
Analysts’ Top Healthcare Picks: Inspire Medical Systems (INSP), Eli Lilly & Co (LLY)
TipRanks · 1d ago
Analysts Offer Insights on Healthcare Companies: Pacific Biosciences (PACB) and Eli Lilly & Co (LLY)
TipRanks · 1d ago
Weight-loss drug developer Metsera raises $290 million in funding
Weight-loss drug developer Metsera raises $290 million in funding. The company is developing injectable and oral drugs to treat obesity. Multiple drug companies are competing to grab a slice of the weight-loss market. The market is estimated to reach $100 billion by the end of the decade.
Reuters · 1d ago
Analysts Are Bullish on Top Healthcare Stocks: Abbott Labs (ABT), US Physical Therapy (USPH)
TipRanks · 1d ago
Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), Zoetis (ZTS) and TScan Therapeutics (TCRX)
TipRanks · 1d ago
The Zacks Analyst Blog Highlights Eli Lilly, Linde, Caterpillar, Salesforce, and Wells Fargo
NASDAQ · 1d ago
U.S. RESEARCH ROUNDUP- Builders Firstsource, Eli Lilly, Northern Trust
Wall Street analysts revise their ratings and price targets on several U.S.-listed companies. Builders Firstsource, Eli Lilly, Northern Trust and Abbott Laboratories are among those. Alphabet Inc raises its target price to $165 from $160. TenX Genomics Inc, a maker of DNA sequencing equipment, is downgraded to hold from sell.
Reuters · 1d ago
Analysts Expect This 'Strong Buy' Weight-Loss Stock to Double
Structure Therapeutics (GPCR) is a clinical-stage biopharma company that went public in 2023. The company is developing a weight-loss drug that aims to treat diabetes and obesity. Cantor Fitzgerald has a price target of $65 for GPCR stock. The stock has an upside potential of 117% from current levels.
Barchart · 1d ago
More
Webull provides a variety of real-time LLY stock news. You can receive the latest news about Lilly Eli & Co through multiple platforms. This information may help you make smarter investment decisions.
About LLY
Eli Lilly and Company is engaged in drug manufacturing businesses. The Company discovers, develops, manufactures and markets products in the human pharmaceutical products segment. Its diabetes, obesity and other cardiometabolic products include Basaglar, Humalog, Humulin, Jardiance, Mounjaro, Trulicity and Zepbound. Its oncology products include Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt and Verzenio. Its immunology products include Ebglyss, Olumiant, Omvoh and Taltz. Its neuroscience products include Cymbalta and Emgality. Its other products and therapies include Cialis and Forteo. The Company manufactures and distributes its products through facilities in the United States (U.S.), including Puerto Rico, and in Europe and Asia. The Company, through its subsidiary, POINT Biopharma Global Inc., is engaged in radiopharmaceutical discovery, development, and manufacturing, as well as clinical and pre-clinical radioligand therapies in development for the treatment of cancer.